首页 > 最新文献

Surgical Oncology-Oxford最新文献

英文 中文
Risk factors for postoperative malignant progression of lower-grade gliomas: a systematic review and meta-analysis 低级别胶质瘤术后恶性进展的危险因素:系统回顾和荟萃分析。
IF 2.4 4区 医学 Q3 ONCOLOGY Pub Date : 2026-02-01 Epub Date: 2025-11-12 DOI: 10.1016/j.suronc.2025.102327
Zhengmao Ge , Guyu Jin , Hongkang Wang , Shimin Wang , Xiaowei Fei , Shuyang Li , Lei Zhang , Xiaofan Jiang , Yanyu Zhang

Objectives

The primary aim was to evaluate the risk factors for postoperative malignant progression of lower-grade glioma (LGG) in patients.

Data sources

PubMed, EMBASE, Web of Science and Cochrane Library were searched from database inception to August 2024.

Eligibility criteria

Quantitative and original studies reporting risk factors for postoperative malignant progression of LGGs were included.

Results

17 observational studies with 3810 glioma patients met the inclusion criteria. Factors including advanced age (HR 1.011, p = 0.042), contrast enhancement (HR 1.540, p = 0.001), rapid expanding speed (HR 4.525, p < 0.001), location in insular lobe (HR 1.514, p = 0.020), eloquence involved (HR 2.413, p < 0.001) and corpus callosum involved (HR 1.695, p = 0.002) were identified as risk factors of postoperative malignant progression of LGGs. High Karnofsky Performance Status (KPS) score (HR 0.955, p = 0.001), oligodendroglioma (HR 0.603, p < 0.001), oligoastrocytoma (HR 0.693, p = 0.016), isocitrate dehydrogenase (IDH) mutation (HR 0.406, p = 0.004), 1p19q codeletion (HR 0.534, p < 0.001), O6-methylguanine-DNA methyltransferase promoter (MGMTP) methylation (HR 0.539, p = 0.007), resection operation (HR 0.277, p < 0.001) and high extent of resection (EOR) (HR 0.972, p = 0.038) were identified as factors that decreased the risk of postoperative malignant progression of LGGs.

Conclusion

This review identified multiple factors associated with the risk of postoperative malignant progression of LGGs, with moderate to high certainty of evidence supporting several key risk and protective factors. Surgeons should be aware of these factors and consider implementing more active treatment and surveillance measures for high-risk patients to improve prognosis.
目的:主要目的是评估低级别胶质瘤(LGG)患者术后恶性进展的危险因素。数据来源:PubMed、EMBASE、Web of Science、Cochrane Library检索自建库至2024年8月。入选标准:纳入报告lgg术后恶性进展危险因素的定量和原始研究。结果:17项观察性研究3810例胶质瘤患者符合纳入标准。影响因素包括高龄(HR 1.011, p = 0.042)、对比增强(HR 1.540, p = 0.001)、扩张速度快(HR 4.525, p 6-甲基鸟嘌呤- dna甲基转移酶启动子(MGMTP)甲基化(HR 0.539, p = 0.007)、切除手术(HR 0.277, p)。结论:本研究确定了与LGGs术后恶性进展风险相关的多个因素,其中一些关键风险和保护因素的证据具有中等至高的确定性。外科医生应意识到这些因素,并考虑对高危患者实施更积极的治疗和监测措施,以改善预后。
{"title":"Risk factors for postoperative malignant progression of lower-grade gliomas: a systematic review and meta-analysis","authors":"Zhengmao Ge ,&nbsp;Guyu Jin ,&nbsp;Hongkang Wang ,&nbsp;Shimin Wang ,&nbsp;Xiaowei Fei ,&nbsp;Shuyang Li ,&nbsp;Lei Zhang ,&nbsp;Xiaofan Jiang ,&nbsp;Yanyu Zhang","doi":"10.1016/j.suronc.2025.102327","DOIUrl":"10.1016/j.suronc.2025.102327","url":null,"abstract":"<div><h3>Objectives</h3><div>The primary aim was to evaluate the risk factors for postoperative malignant progression of lower-grade glioma (LGG) in patients.</div></div><div><h3>Data sources</h3><div>PubMed, EMBASE, Web of Science and Cochrane Library were searched from database inception to August 2024.</div></div><div><h3>Eligibility criteria</h3><div>Quantitative and original studies reporting risk factors for postoperative malignant progression of LGGs were included.</div></div><div><h3>Results</h3><div>17 observational studies with 3810 glioma patients met the inclusion criteria. Factors including advanced age (HR 1.011, p = 0.042), contrast enhancement (HR 1.540, p = 0.001), rapid expanding speed (HR 4.525, p &lt; 0.001), location in insular lobe (HR 1.514, p = 0.020), eloquence involved (HR 2.413, p &lt; 0.001) and corpus callosum involved (HR 1.695, p = 0.002) were identified as risk factors of postoperative malignant progression of LGGs. High Karnofsky Performance Status (KPS) score (HR 0.955, p = 0.001), oligodendroglioma (HR 0.603, p &lt; 0.001), oligoastrocytoma (HR 0.693, p = 0.016), isocitrate dehydrogenase (IDH) mutation (HR 0.406, p = 0.004), 1p19q codeletion (HR 0.534, p &lt; 0.001), O<sup>6</sup>-methylguanine-DNA methyltransferase promoter (MGMTP) methylation (HR 0.539, p = 0.007), resection operation (HR 0.277, p &lt; 0.001) and high extent of resection (EOR) (HR 0.972, p = 0.038) were identified as factors that decreased the risk of postoperative malignant progression of LGGs.</div></div><div><h3>Conclusion</h3><div>This review identified multiple factors associated with the risk of postoperative malignant progression of LGGs, with moderate to high certainty of evidence supporting several key risk and protective factors. Surgeons should be aware of these factors and consider implementing more active treatment and surveillance measures for high-risk patients to improve prognosis.</div></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"64 ","pages":"Article 102327"},"PeriodicalIF":2.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145534854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Survival benefit of resectability determined by multiple surgeons in BCLC-C Stage: A single-center cohort study 多名外科医生决定BCLC-C期可切除性的生存获益:一项单中心队列研究。
IF 2.4 4区 医学 Q3 ONCOLOGY Pub Date : 2026-02-01 Epub Date: 2025-11-08 DOI: 10.1016/j.suronc.2025.102328
Kyung Chul Yoon , Sanggyun Suh , YoungRok Choi , Jeong-Moo Lee , Minseob Kim , Jaewon Lee , Jae-Yoon Kim , Jiyoung Kim , Won-Gun Yun , Chang-Sup Lim , Su young Hong , Suk Kyun Hong , Nam-Joon Yi , Kwang-Woong Lee , Kyung-Suk Suh

Background

Systemic therapy remains the standard treatment for Barcelona Clinic Liver Cancer Stage C (BCLC C). However, the heterogeneity of this patient cohort has prompted investigation into alternative or additional therapeutic approaches. Potential bias exists in previous comparisons among treatment groups. Therefore, we compared survival outcomes between resectable and unresectable groups, as determined by four experienced surgeons.

Methods

We used data from patients who were initially diagnosed with liver cancer and treated at Seoul National University Hospital from January 2015 to December 2017. Four experienced liver surgeons participated, and each patient was classified as 'resectable' only when the two reviewing surgeons agreed that it was 'resectable’ based on medical records and imaging.

Results

The cohort included 1351 patients, of whom 212 had BCLC C. Among them, 162 were classified as resectable and 50 as unresectable. Portal vein tumor thrombus was present in 92.6 % and 86 % in the unresectable and resectable groups, respectively. The resectable group had better survival rates than the unresectable group, with 1-, 3-, and 5-year survival rates of 75.4, 52.3, and 45.1 % vs. 47 %, 22.2 %, and 13 %, respectively (P < 0.01). In the resectable group, 21 patients underwent resection and 28 received transarterial chemoembolization. The resection subgroup demonstrated superior 1-, 3-, and 5-year survival rates: 90.2 %, 75.2 %, and 64.4 %, vs. 63.1 %, 33.4 %, and 28.7 %, respectively (P < 0.01). Bile duct invasion (HR: 0.6477 [1.309–32.05], P = 0.02) and resection (HR: 0.247 [0.072–0.854], P = 0.02) were significant factors for OS.

Conclusions

Determining resectability at the BCLC-C stage and performing resection may improve survival.
背景:全身治疗仍然是巴塞罗那临床C期肝癌(BCLC - C)的标准治疗方法。然而,该患者队列的异质性促使对替代或额外治疗方法的研究。先前治疗组间的比较存在潜在的偏倚。因此,我们比较了可切除组和不可切除组的生存结果,由四位经验丰富的外科医生确定。方法:我们使用了2015年1月至2017年12月在首尔国立大学医院首次诊断为肝癌并接受治疗的患者的数据。四名经验丰富的肝脏外科医生参与了调查,只有当两名审查的外科医生根据医疗记录和影像学检查一致认为可以“切除”时,每位患者才会被归类为“可切除”。结果:纳入1351例患者,其中BCLC c 212例,可切除162例,不可切除50例。不可切除组和可切除组门静脉肿瘤血栓发生率分别为92.6%和86%。可切除组的生存率高于不可切除组,1年、3年和5年生存率分别为75.4、52.3%和45.1%,而不可切除组分别为47%、22.2%和13% (P结论:在BCLC-C期确定可切除性并进行切除可提高生存率。
{"title":"Survival benefit of resectability determined by multiple surgeons in BCLC-C Stage: A single-center cohort study","authors":"Kyung Chul Yoon ,&nbsp;Sanggyun Suh ,&nbsp;YoungRok Choi ,&nbsp;Jeong-Moo Lee ,&nbsp;Minseob Kim ,&nbsp;Jaewon Lee ,&nbsp;Jae-Yoon Kim ,&nbsp;Jiyoung Kim ,&nbsp;Won-Gun Yun ,&nbsp;Chang-Sup Lim ,&nbsp;Su young Hong ,&nbsp;Suk Kyun Hong ,&nbsp;Nam-Joon Yi ,&nbsp;Kwang-Woong Lee ,&nbsp;Kyung-Suk Suh","doi":"10.1016/j.suronc.2025.102328","DOIUrl":"10.1016/j.suronc.2025.102328","url":null,"abstract":"<div><h3>Background</h3><div>Systemic therapy remains the standard treatment for Barcelona Clinic Liver Cancer Stage C (BCLC C). However, the heterogeneity of this patient cohort has prompted investigation into alternative or additional therapeutic approaches. Potential bias exists in previous comparisons among treatment groups. Therefore, we compared survival outcomes between resectable and unresectable groups, as determined by four experienced surgeons.</div></div><div><h3>Methods</h3><div>We used data from patients who were initially diagnosed with liver cancer and treated at Seoul National University Hospital from January 2015 to December 2017. Four experienced liver surgeons participated, and each patient was classified as 'resectable' only when the two reviewing surgeons agreed that it was 'resectable’ based on medical records and imaging.</div></div><div><h3>Results</h3><div>The cohort included 1351 patients, of whom 212 had BCLC C. Among them, 162 were classified as resectable and 50 as unresectable. Portal vein tumor thrombus was present in 92.6 % and 86 % in the unresectable and resectable groups, respectively. The resectable group had better survival rates than the unresectable group, with 1-, 3-, and 5-year survival rates of 75.4, 52.3, and 45.1 % vs. 47 %, 22.2 %, and 13 %, respectively (P &lt; 0.01). In the resectable group, 21 patients underwent resection and 28 received transarterial chemoembolization. The resection subgroup demonstrated superior 1-, 3-, and 5-year survival rates: 90.2 %, 75.2 %, and 64.4 %, vs. 63.1 %, 33.4 %, and 28.7 %, respectively (P &lt; 0.01). Bile duct invasion (HR: 0.6477 [1.309–32.05], P = 0.02) and resection (HR: 0.247 [0.072–0.854], P = 0.02) were significant factors for OS.</div></div><div><h3>Conclusions</h3><div>Determining resectability at the BCLC-C stage and performing resection may improve survival.</div></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"64 ","pages":"Article 102328"},"PeriodicalIF":2.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145514691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identification of TRACP 5b as a local recurrence biomarker in giant cell tumor of bone 骨巨细胞瘤局部复发标志物TRACP 5b的鉴定
IF 2.4 4区 医学 Q3 ONCOLOGY Pub Date : 2026-02-01 Epub Date: 2025-11-19 DOI: 10.1016/j.suronc.2025.102331
Yu Toda, Koichi Ogura, Shintaro Iwata, Eisuke Kobayashi, Shuhei Osaki, Suguru Fukushima, Akira Kawai

Background

Giant cell tumor of bone (GCTB) has a high potential for local recurrence after surgical treatment. It is characterized by the histological proliferation of osteoclast-like multinucleated giant cells. Tartrate-resistant acid phosphatase 5b (TRACP5b) is a reliable serum marker of bone resorption. This study aimed to investigate the impact of TRACP5b levels on the local recurrence of GCTB following surgical treatment.

Methods

We retrospectively analyzed data from 47 primary GCTB patients who underwent serum TRACP5b testing and surgical treatment between 2015 and 2022. We statistically evaluated the correlation between TRACP5b levels and clinical characteristics. Patients were stratified into two groups based on TRACP5b levels, and the association between TRACP5b and local recurrence was assessed across various clinical parameters.

Results

The mean TRACP5b level in male patients (2062 ± 2289 mU/dL) was significantly higher than in female patients (976 ± 487 mU/dL; p = 0.048). A moderate positive correlation was observed between tumor size and TRACP5b levels (r = 0.586, p < 0.001). Gender, tumor location (trunk, lower extremity, and upper extremity), tumor size, and TRACP5b levels were significantly associated with local recurrence-free survival (p values were 0.037, 0.0006, 0.048, and 0.004, respectively).

Conclusions

This study identified preoperative TRACP5b levels as a prognostic factor for local recurrence in GCTB patients, highlighting its potential utility in risk stratification and personalized management.
背景骨巨细胞瘤(GCTB)在手术治疗后有很高的局部复发可能性。其特点是破骨细胞样多核巨细胞的组织学增生。抗酒石酸酸性磷酸酶5b (TRACP5b)是一种可靠的骨吸收血清标志物。本研究旨在探讨TRACP5b水平对GCTB手术后局部复发的影响。方法回顾性分析2015年至2022年47例接受血清TRACP5b检测和手术治疗的原发性GCTB患者的资料。我们统计评估TRACP5b水平与临床特征的相关性。根据TRACP5b水平将患者分为两组,并通过各种临床参数评估TRACP5b与局部复发之间的关系。结果男性患者的平均TRACP5b水平(2062±2289 mU/dL)显著高于女性患者(976±487 mU/dL, p = 0.048)。肿瘤大小与TRACP5b水平呈正相关(r = 0.586, p < 0.001)。性别、肿瘤位置(躯干、下肢和上肢)、肿瘤大小和TRACP5b水平与局部无复发生存率显著相关(p值分别为0.037、0.0006、0.048和0.004)。结论本研究确定术前TRACP5b水平是GCTB患者局部复发的预后因素,强调其在风险分层和个性化管理中的潜在效用。
{"title":"Identification of TRACP 5b as a local recurrence biomarker in giant cell tumor of bone","authors":"Yu Toda,&nbsp;Koichi Ogura,&nbsp;Shintaro Iwata,&nbsp;Eisuke Kobayashi,&nbsp;Shuhei Osaki,&nbsp;Suguru Fukushima,&nbsp;Akira Kawai","doi":"10.1016/j.suronc.2025.102331","DOIUrl":"10.1016/j.suronc.2025.102331","url":null,"abstract":"<div><h3>Background</h3><div>Giant cell tumor of bone (GCTB) has a high potential for local recurrence after surgical treatment. It is characterized by the histological proliferation of osteoclast-like multinucleated giant cells. Tartrate-resistant acid phosphatase 5b (TRACP5b) is a reliable serum marker of bone resorption. This study aimed to investigate the impact of TRACP5b levels on the local recurrence of GCTB following surgical treatment.</div></div><div><h3>Methods</h3><div>We retrospectively analyzed data from 47 primary GCTB patients who underwent serum TRACP5b testing and surgical treatment between 2015 and 2022. We statistically evaluated the correlation between TRACP5b levels and clinical characteristics. Patients were stratified into two groups based on TRACP5b levels, and the association between TRACP5b and local recurrence was assessed across various clinical parameters.</div></div><div><h3>Results</h3><div>The mean TRACP5b level in male patients (2062 ± 2289 mU/dL) was significantly higher than in female patients (976 ± 487 mU/dL; p = 0.048). A moderate positive correlation was observed between tumor size and TRACP5b levels (r = 0.586, p &lt; 0.001). Gender, tumor location (trunk, lower extremity, and upper extremity), tumor size, and TRACP5b levels were significantly associated with local recurrence-free survival (p values were 0.037, 0.0006, 0.048, and 0.004, respectively).</div></div><div><h3>Conclusions</h3><div>This study identified preoperative TRACP5b levels as a prognostic factor for local recurrence in GCTB patients, highlighting its potential utility in risk stratification and personalized management.</div></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"64 ","pages":"Article 102331"},"PeriodicalIF":2.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145579571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Robotic bona fide right hepatectomy with ICG-guided detachment technique 基于icg引导下脱离技术的机器人真实右肝切除术
IF 2.4 4区 医学 Q3 ONCOLOGY Pub Date : 2026-02-01 Epub Date: 2025-12-02 DOI: 10.1016/j.suronc.2025.102338
Taiga Wakabayashi, Sara Pepe, Muhammad Naeem, Go Wakabayashi

Background

Anatomic liver resection (ALR) requires precise transection along the true intersegmental/sectional plane while preserving vascular integrity of the remnant liver. Conventional approaches often rely on ischemic demarcation or venous landmarks, which may not perfectly match anatomical boundaries. Robotic platforms and indocyanine green (ICG) fluorescence have enabled refined visualization and dexterity, supporting the concept of bona fide ALR—defined as anatomical resection that exactly follows the Glissonean territory while preserving remnant inflow and outflow integrity. The “detachment technique” denotes a robotic ICG-guided approach that achieves natural parenchymal separation along the demarcated plane through controlled traction–countertraction dynamics, ensuring anatomical precision without unnecessary vessel sacrifice. Conceptually, this principle applies to any segmental or subsegmental unit of the liver representing the smallest anatomical territory supplied by a Glissonean pedicle.

Methods

We report robotic right hepatectomy in a woman in her 50s with abdominal fullness due to a giant hepatic hemangioma. Using the Da Vinci Xi system, cystic plate cholecystectomy was performed, and the right hepatic artery was ligated to reduce tumor tension. After encirclement of the hepatoduodenal ligament, the right Glissonean pedicle was isolated using an extrahepatic approach. Intravenous injection of 0.25 mg ICG enabled negative staining, which delineated the transection plane. Parenchymal transection was carried out with a Maryland bipolar dissector under robotic countertraction, facilitating natural detachment along the Main Portal Fissure. Firefly mode provided real-time visualization, and the anterior and posterior Glissonean pedicles and the right hepatic vein were divided with staplers.

Results

The procedure was completed in 407 minutes with an estimated blood loss of 116 mL. The postoperative course was uneventful, and the patient was discharged on postoperative day 7.

Conclusion

Robotic right hepatectomy with a Glissonean approach and ICG-guided negative staining illustrates the feasibility of bona fide anatomic liver resection (ALR). While demonstrated in a single case of hemangioma, this technique requires expertise in the extrahepatic Glissonean approach and should be validated in multicentric cohorts to assess its generalizability and long-term outcomes.
背景:原子肝切除术(ALR)需要沿着真正的节段间/切面进行精确的横切,同时保持残肝的血管完整性。传统的入路通常依赖于缺血划分或静脉标记,这可能与解剖边界不完全匹配。机器人平台和吲哚菁绿(ICG)荧光实现了精细的可视化和灵巧性,支持真正的alr概念,定义为精确遵循格利索内区域的解剖切除,同时保持残余流入和流出的完整性。“脱离技术”是一种机器人icg引导下的方法,通过控制牵引-反牵引动力学,沿着划定平面实现自然的实质分离,确保解剖精度,而不牺牲不必要的血管。从概念上讲,这一原则适用于肝脏的任何节段或亚节段单位,代表由格利索内蒂提供的最小解剖区域。方法我们报告一位50多岁因巨大肝血管瘤而腹部充盈的女性右肝机器人切除术。采用Da Vinci Xi系统行胆囊板胆囊切除术,结扎肝右动脉以降低肿瘤张力。围合肝十二指肠韧带后,采用肝外入路分离右格利索内蒂。静脉注射0.25 mg ICG,使其呈阴性染色,描绘横切面。在机器人反牵引下,使用马里兰双极解剖器进行实质横断,促进沿门静脉主裂自然脱离。Firefly模式提供实时可视化,用吻合器将Glissonean蒂前后及右肝静脉分开。结果手术在407分钟内完成,估计失血量为116 mL。术后过程平稳,患者于术后第7天出院。结论采用Glissonean入路和icg引导阴性染色的机器人右肝切除术证明了真实解剖肝切除术(ALR)的可行性。虽然在单个血管瘤病例中得到证实,但该技术需要肝外Glissonean入路的专业知识,并应在多中心队列中进行验证,以评估其广泛性和长期结果。
{"title":"Robotic bona fide right hepatectomy with ICG-guided detachment technique","authors":"Taiga Wakabayashi,&nbsp;Sara Pepe,&nbsp;Muhammad Naeem,&nbsp;Go Wakabayashi","doi":"10.1016/j.suronc.2025.102338","DOIUrl":"10.1016/j.suronc.2025.102338","url":null,"abstract":"<div><h3>Background</h3><div>Anatomic liver resection (ALR) requires precise transection along the true intersegmental/sectional plane while preserving vascular integrity of the remnant liver. Conventional approaches often rely on ischemic demarcation or venous landmarks, which may not perfectly match anatomical boundaries. Robotic platforms and indocyanine green (ICG) fluorescence have enabled refined visualization and dexterity, supporting the concept of bona fide ALR—defined as anatomical resection that exactly follows the Glissonean territory while preserving remnant inflow and outflow integrity. The “detachment technique” denotes a robotic ICG-guided approach that achieves natural parenchymal separation along the demarcated plane through controlled traction–countertraction dynamics, ensuring anatomical precision without unnecessary vessel sacrifice. Conceptually, this principle applies to any segmental or subsegmental unit of the liver representing the smallest anatomical territory supplied by a Glissonean pedicle.</div></div><div><h3>Methods</h3><div>We report robotic right hepatectomy in a woman in her 50s with abdominal fullness due to a giant hepatic hemangioma. Using the Da Vinci Xi system, cystic plate cholecystectomy was performed, and the right hepatic artery was ligated to reduce tumor tension. After encirclement of the hepatoduodenal ligament, the right Glissonean pedicle was isolated using an extrahepatic approach. Intravenous injection of 0.25 mg ICG enabled negative staining, which delineated the transection plane. Parenchymal transection was carried out with a Maryland bipolar dissector under robotic countertraction, facilitating natural detachment along the Main Portal Fissure. Firefly mode provided real-time visualization, and the anterior and posterior Glissonean pedicles and the right hepatic vein were divided with staplers.</div></div><div><h3>Results</h3><div>The procedure was completed in 407 minutes with an estimated blood loss of 116 mL. The postoperative course was uneventful, and the patient was discharged on postoperative day 7.</div></div><div><h3>Conclusion</h3><div>Robotic right hepatectomy with a Glissonean approach and ICG-guided negative staining illustrates the feasibility of bona fide anatomic liver resection (ALR). While demonstrated in a single case of hemangioma, this technique requires expertise in the extrahepatic Glissonean approach and should be validated in multicentric cohorts to assess its generalizability and long-term outcomes.</div></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"64 ","pages":"Article 102338"},"PeriodicalIF":2.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145693724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comprehensive guide to the diagnosis, management, and treatment of metastatic spinal cord compression syndrome 转移性脊髓压迫综合征的诊断、管理和治疗的综合指南。
IF 2.4 4区 医学 Q3 ONCOLOGY Pub Date : 2026-02-01 Epub Date: 2025-12-13 DOI: 10.1016/j.suronc.2025.102341
Daniel Alejandro Vega Moreno , Gervith Reyes Soto , Julio Cesar Lopez-Valdes , Alfonso Arellano-Mata , Henar Galicia Palacios , Miguel Agustín Amador Hernandez , Manuel de Jesús Encarnación-Ramirez
Spinal metastases are the most common tumors found in the neuraxis. They correspond to 90 % of all tumors at this level. The thoracic region is the most frequently affected area, followed by the lumbar region, with the cervical region being the least frequently affected place. Back pain is the most common symptom, appearing in up to 95 % of patients who present with spinal cord compression syndrome. The evaluation of patients with spinal cord compression syndrome is complex and requires an entire multidisciplinary team for diagnosis, management, and treatment. In the medical part, treatment is based on pain control with analgesic medications and the use of steroids, mainly dexamethasone, which has demonstrated efficacy and safety in the context of patients with spinal cord compression syndrome for functional recovery. Radiotherapy treatment is essential both as a definitive treatment and as a complementary treatment to surgery and although to date there are several treatment schemes, doses and fractions must be individualized based on the clinical context of each patient. On the other hand, metastatic spinal surgery is considered part of the definitive treatment, and although in a palliative context there are multiple approaches and indications for it. The importance of considering surgery is in those patients who are unstable since surgery, although it is not curative, poses a substantial improvement in symptoms as well as in pain recovery. We propose a diagnosis and treatment algorithm for patients with metastatic spinal cord compression syndrome in which decision-making is based on individualization and joint management by a multidisciplinary team.

Clinical trial number

not applicable.
脊髓转移瘤是神经轴最常见的肿瘤。90%的肿瘤都属于这一级别。胸部是最常见的受累部位,其次是腰椎,颈椎是最不常见的受累部位。背部疼痛是最常见的症状,出现在95%的脊髓压迫综合征患者中。脊髓压迫综合征患者的评估是复杂的,需要一个完整的多学科团队进行诊断、管理和治疗。在医疗方面,治疗是基于镇痛药物控制疼痛和使用类固醇,主要是地塞米松,这在脊髓压迫综合征患者功能恢复的情况下已被证明是有效和安全的。放射治疗作为一种决定性治疗和手术的补充治疗是必不可少的,尽管迄今为止有几种治疗方案,但剂量和剂量必须根据每位患者的临床情况进行个体化。另一方面,转移性脊柱手术被认为是最终治疗的一部分,尽管在姑息性背景下有多种方法和适应症。考虑手术的重要性是在那些不稳定的患者,因为手术虽然不能治愈,但在症状和疼痛恢复方面有很大的改善。我们提出了一种转移性脊髓压迫综合征患者的诊断和治疗算法,其中决策基于个体化和多学科团队的联合管理。临床试验编号:不适用。
{"title":"Comprehensive guide to the diagnosis, management, and treatment of metastatic spinal cord compression syndrome","authors":"Daniel Alejandro Vega Moreno ,&nbsp;Gervith Reyes Soto ,&nbsp;Julio Cesar Lopez-Valdes ,&nbsp;Alfonso Arellano-Mata ,&nbsp;Henar Galicia Palacios ,&nbsp;Miguel Agustín Amador Hernandez ,&nbsp;Manuel de Jesús Encarnación-Ramirez","doi":"10.1016/j.suronc.2025.102341","DOIUrl":"10.1016/j.suronc.2025.102341","url":null,"abstract":"<div><div>Spinal metastases are the most common tumors found in the neuraxis. They correspond to 90 % of all tumors at this level. The thoracic region is the most frequently affected area, followed by the lumbar region, with the cervical region being the least frequently affected place. Back pain is the most common symptom, appearing in up to 95 % of patients who present with spinal cord compression syndrome. The evaluation of patients with spinal cord compression syndrome is complex and requires an entire multidisciplinary team for diagnosis, management, and treatment. In the medical part, treatment is based on pain control with analgesic medications and the use of steroids, mainly dexamethasone, which has demonstrated efficacy and safety in the context of patients with spinal cord compression syndrome for functional recovery. Radiotherapy treatment is essential both as a definitive treatment and as a complementary treatment to surgery and although to date there are several treatment schemes, doses and fractions must be individualized based on the clinical context of each patient. On the other hand, metastatic spinal surgery is considered part of the definitive treatment, and although in a palliative context there are multiple approaches and indications for it. The importance of considering surgery is in those patients who are unstable since surgery, although it is not curative, poses a substantial improvement in symptoms as well as in pain recovery. We propose a diagnosis and treatment algorithm for patients with metastatic spinal cord compression syndrome in which decision-making is based on individualization and joint management by a multidisciplinary team.</div></div><div><h3>Clinical trial number</h3><div>not applicable.</div></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"64 ","pages":"Article 102341"},"PeriodicalIF":2.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145783657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cavity shave technique for safe resection margins in breast cancer conserving surgery: a randomized clinical trial 乳腺癌保癌手术中安全切除边缘的刮腔技术:随机临床试验。
IF 2.4 4区 医学 Q3 ONCOLOGY Pub Date : 2026-02-01 Epub Date: 2025-10-30 DOI: 10.1016/j.suronc.2025.102315
Gianluca Vanni , Marco Pellicciaro , Marco Materazzo , Alice Bertolo , Denisa Eskiu , Alessia Petricca , Michele Treglia , Benedetto Longo , Valerio Cervelli , Oreste Claudio Buonomo

Background/aim

In the modern era, breast surgery aims to adopt conservative strategies that ensure both oncological safety and aesthetic outcomes. However, one of the major challenges is the risk of positive margins, which may require a second surgery. Various strategies have been adopted to minimize this risk. The most commonly used strategies include the selective resection of suspicious margins after intraoperative evaluation and the routine circumferential resection of additional tissue around the cavity left by a lumpectomy, known as the Cavity-Shave (CS) Technique.

Methods

A blind randomized clinical trial was conducted, in which standard selective margin resections were compared to the CS technique, in a 1:1 ratio, comparing oncological outcomes, aesthetic results, and surgical time.

Results

A total of 185 patients were enrolled in the study, with a mean age of 62.04 ± 14.02. The sample was randomly assigned to two groups: 91(49.2 %) were allocated to the cavity shave (CS) Group and 94 (50.8 %) to the no-CS-Group. The rate of positive margins was 20.9 % versus 18.1 %, p-value:0.631 vs p-value:0.577. The re-excision rate was 12.1 % vs 14.9 %, in the CS-group and in the no-Cs-Group respectively. The mean operating room occupancy time was 77.9 ± 23.5 min in the CS-group versus 95.6 ± 34.9 min in the no-Cs-Group, with a p-value<0.001. Aesthetic outcomes were comparable between the two groups (p-value:0.706), despite a statistically significant difference in the total volume excised, 67.2 ± 16.4 cm3 in the CS-Group versus 51.5 ± 17.2 cm3 in the no-CS-Group, p-value:0.021.

Conclusion

CS and selective margin resection with intraoperative histopathological evaluation showed similar oncological and aesthetic outcomes; however, CS was associated with a statistically significant reduction in surgical time.
背景/目的:在现代,乳房手术旨在采用保守策略,以确保肿瘤安全和美观效果。然而,主要的挑战之一是正切的风险,这可能需要第二次手术。采取了各种策略来尽量减少这种风险。最常用的策略包括术中评估后选择性切除可疑边缘,以及常规切除乳房肿瘤切除术后留下的腔周围额外组织,称为腔剃(CS)技术。方法:进行盲随机临床试验,将标准选择性切缘切除术与CS技术按1:1的比例进行比较,比较肿瘤预后、美观效果和手术时间。结果:共入组185例患者,平均年龄62.04±14.02岁。将样本随机分为两组:91例(49.2%)分为刮刀组(CS), 94例(50.8%)分为不刮刀组(CS)。阳性边缘率分别为20.9%和18.1%,p值分别为0.631和0.577。cs组和无cs组的再切除率分别为12.1%和14.9%。cs组平均手术室占用时间为77.9±23.5 min,无cs组为95.6±34.9 min, p值为3,无cs组为51.5±17.2 cm3, p值为0.021。结论:CS与选择性切缘切除术中组织病理学评价具有相似的肿瘤学和美学结果;然而,CS与手术时间的减少有统计学意义。
{"title":"Cavity shave technique for safe resection margins in breast cancer conserving surgery: a randomized clinical trial","authors":"Gianluca Vanni ,&nbsp;Marco Pellicciaro ,&nbsp;Marco Materazzo ,&nbsp;Alice Bertolo ,&nbsp;Denisa Eskiu ,&nbsp;Alessia Petricca ,&nbsp;Michele Treglia ,&nbsp;Benedetto Longo ,&nbsp;Valerio Cervelli ,&nbsp;Oreste Claudio Buonomo","doi":"10.1016/j.suronc.2025.102315","DOIUrl":"10.1016/j.suronc.2025.102315","url":null,"abstract":"<div><h3>Background/aim</h3><div>In the modern era, breast surgery aims to adopt conservative strategies that ensure both oncological safety and aesthetic outcomes. However, one of the major challenges is the risk of positive margins, which may require a second surgery. Various strategies have been adopted to minimize this risk. The most commonly used strategies include the selective resection of suspicious margins after intraoperative evaluation and the routine circumferential resection of additional tissue around the cavity left by a lumpectomy, known as the Cavity-Shave (CS) Technique.</div></div><div><h3>Methods</h3><div>A blind randomized clinical trial was conducted, in which standard selective margin resections were compared to the CS technique, in a 1:1 ratio, comparing oncological outcomes, aesthetic results, and surgical time.</div></div><div><h3>Results</h3><div>A total of 185 patients were enrolled in the study, with a mean age of 62.04 ± 14.02. The sample was randomly assigned to two groups: 91(49.2 %) were allocated to the cavity shave (CS) Group and 94 (50.8 %) to the no-CS-Group. The rate of positive margins was 20.9 % versus 18.1 %, p-value:0.631 vs p-value:0.577. The re-excision rate was 12.1 % vs 14.9 %, in the CS-group and in the no-Cs-Group respectively. The mean operating room occupancy time was 77.9 ± 23.5 min in the CS-group versus 95.6 ± 34.9 min in the no-Cs-Group, with a p-value&lt;0.001. Aesthetic outcomes were comparable between the two groups (p-value:0.706), despite a statistically significant difference in the total volume excised, 67.2 ± 16.4 cm<sup>3</sup> in the CS-Group versus 51.5 ± 17.2 cm<sup>3</sup> in the no-CS-Group, p-value:0.021.</div></div><div><h3>Conclusion</h3><div>CS and selective margin resection with intraoperative histopathological evaluation showed similar oncological and aesthetic outcomes; however, CS was associated with a statistically significant reduction in surgical time.</div></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"64 ","pages":"Article 102315"},"PeriodicalIF":2.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145460312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of minimally invasive surgical approach on oncological completeness of resection in lung cancer surgery 微创手术入路对肺癌手术肿瘤切除完整性的影响。
IF 2.4 4区 医学 Q3 ONCOLOGY Pub Date : 2026-02-01 Epub Date: 2025-10-28 DOI: 10.1016/j.suronc.2025.102310
Clara Forcada , María Teresa Gómez-Hernández , Cristina E. Rivas , Marta G. Fuentes , Óscar Colmenares , Mario Manama , José Luis Aranda , Marta Rodríguez , Mercedes Sánchez , Marcelo F. Jiménez

Objectives

Oncological radicality, defined as complete resection, is essential in lung cancer surgery. This study aimed to compare the oncological quality of anatomical lung resections performed via video-assisted thoracoscopic surgery (VATS) versus robotic-assisted thoracic surgery (RATS), focusing on completeness of resection. Secondary objectives included lymphadenectomy quality, nodal upstaging, residual disease, and the number of dissected lymph node stations and retrieved lymph nodes.

Methods

A prospective single-center study included consecutive patients undergoing minimally invasive anatomical lung resection for lung cancer (September 2023–April 2025). Overlap weighting based on propensity scores—calculated using histology, clinical T and N stage, and extent of resection—was applied. Outcomes related to oncological radicality were compared between the VATS and RATS groups using appropriate statistical tests based on variable type and distribution.

Results

Of 358 patients, 255 met the inclusion criteria (84 RATS, 171 VATS). The rates of complete, incomplete, and uncertain resection were 62.0 %, 3.5 %, and 34.5 %, respectively. After overlap weighting, no significant differences were observed between RATS and VATS in complete resection (66.5 % vs. 60 %, p = 0.557), residual disease (2.17 % vs. 1.92 %, p = 0.802), adequate lymphadenectomy (70.7 % vs. 61.8 %, p = 0.181), or nodal upstaging (19.7 % vs. 11.3 %, p = 0.087). However, RATS yielded a higher number of mediastinal nodal stations dissected (median: 4 vs. 3, p < 0.001) and lymph nodes retrieved (median: 9 vs. 7, p < 0.001).

Conclusions

RATS and VATS achieved similar oncological radicality. However, RATS was associated with more extensive lymphadenectomy, potentially improving staging accuracy.
目的:肿瘤根治性,定义为完全切除,在肺癌手术中是必不可少的。本研究旨在比较通过视频辅助胸腔镜手术(VATS)和机器人辅助胸外科手术(RATS)进行的解剖性肺切除术的肿瘤学质量,重点是切除的完整性。次要目标包括淋巴结切除术的质量、淋巴结的分期、残留病变、淋巴结清扫和淋巴结回收的数量。方法:一项前瞻性单中心研究纳入了2023年9月至2025年4月连续接受微创解剖性肺癌肺切除术的患者。使用基于倾向评分的重叠加权-使用组织学,临床T和N分期以及切除程度计算。采用基于变量类型和分布的适当统计检验,比较VATS组和RATS组与肿瘤根治性相关的结果。结果:358例患者中,255例符合纳入标准(rat 84例,VATS 171例)。完全切除、不完全切除和不确定切除的比例分别为62.0%、3.5%和34.5%。重叠加权后,大鼠和VATS在完全切除(66.5% vs. 60%, p = 0.557)、残留病变(2.17% vs. 1.92%, p = 0.802)、充分淋巴结切除术(70.7% vs. 61.8%, p = 0.181)或淋巴结分期(19.7% vs. 11.3%, p = 0.087)方面无显著差异。然而,大鼠获得了更高数量的纵隔淋巴结清扫(中位数:4比3,p)。然而,RATS与更广泛的淋巴结切除术相关,可能提高分期准确性。
{"title":"Impact of minimally invasive surgical approach on oncological completeness of resection in lung cancer surgery","authors":"Clara Forcada ,&nbsp;María Teresa Gómez-Hernández ,&nbsp;Cristina E. Rivas ,&nbsp;Marta G. Fuentes ,&nbsp;Óscar Colmenares ,&nbsp;Mario Manama ,&nbsp;José Luis Aranda ,&nbsp;Marta Rodríguez ,&nbsp;Mercedes Sánchez ,&nbsp;Marcelo F. Jiménez","doi":"10.1016/j.suronc.2025.102310","DOIUrl":"10.1016/j.suronc.2025.102310","url":null,"abstract":"<div><h3>Objectives</h3><div>Oncological radicality, defined as complete resection, is essential in lung cancer surgery. This study aimed to compare the oncological quality of anatomical lung resections performed via video-assisted thoracoscopic surgery (VATS) versus robotic-assisted thoracic surgery (RATS), focusing on completeness of resection. Secondary objectives included lymphadenectomy quality, nodal upstaging, residual disease, and the number of dissected lymph node stations and retrieved lymph nodes.</div></div><div><h3>Methods</h3><div>A prospective single-center study included consecutive patients undergoing minimally invasive anatomical lung resection for lung cancer (September 2023–April 2025). Overlap weighting based on propensity scores—calculated using histology, clinical T and N stage, and extent of resection—was applied. Outcomes related to oncological radicality were compared between the VATS and RATS groups using appropriate statistical tests based on variable type and distribution.</div></div><div><h3>Results</h3><div>Of 358 patients, 255 met the inclusion criteria (84 RATS, 171 VATS). The rates of complete, incomplete, and uncertain resection were 62.0 %, 3.5 %, and 34.5 %, respectively. After overlap weighting, no significant differences were observed between RATS and VATS in complete resection (66.5 % vs. 60 %, p = 0.557), residual disease (2.17 % vs. 1.92 %, p = 0.802), adequate lymphadenectomy (70.7 % vs. 61.8 %, p = 0.181), or nodal upstaging (19.7 % vs. 11.3 %, p = 0.087). However, RATS yielded a higher number of mediastinal nodal stations dissected (median: 4 vs. 3, p &lt; 0.001) and lymph nodes retrieved (median: 9 vs. 7, p &lt; 0.001).</div></div><div><h3>Conclusions</h3><div>RATS and VATS achieved similar oncological radicality. However, RATS was associated with more extensive lymphadenectomy, potentially improving staging accuracy.</div></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"64 ","pages":"Article 102310"},"PeriodicalIF":2.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145446554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The impact of the timing of adjuvant treatment initiation in patients with upfront resection of pancreatic cancer 胰腺癌前期切除术患者开始辅助治疗时机的影响
IF 2.4 4区 医学 Q3 ONCOLOGY Pub Date : 2026-02-01 Epub Date: 2025-11-10 DOI: 10.1016/j.suronc.2025.102329
Sydney McManus , Aimée Galatas , Sarah Hemelt , Sanchit Sachdeva , Kevin Sullivan , Bolni Marius Nagalo , Denise Danos , Omeed Moaven

Introduction

This study evaluates the association between timing of adjuvant chemotherapy and overall survival in resectable pancreatic ductal adenocarcinoma (PDAC). It also examines whether the adoption of modern chemotherapy regimens in recent years has influenced this relationship, reflecting evolving treatment practices.

Methods

Cases of resectable primary invasive PDAC were identified using the National Cancer Database (NCDB). Overall survival (OS) was visualized using Kaplan Meier survival plots and Cox proportional hazard models. Covariat adjustment and propensity score matched cohort were analyzed. The matched cohort was analyzed with Cox proportional hazard models and logistic models.

Results

31,949 patients were included in the study. 26.4 % received no chemotherapy, 66.4 % received chemotherapy within 12 weeks, and 7.2 % received chemotherapy after 12 weeks. There was significant improvement in mOS. Between 2015 and 2019, there was a significant difference in OS for patients receiving chemotherapy within 12 weeks, compared to >12 weeks.

Conclusion

While adjuvant chemotherapy in patients with resectable PDAC is associated with improved OS compared to no adjuvant therapy, it is worth considering that those who are well enough to receive chemotherapy inherently have better prognoses. Importantly, the survival association persists regardless of the timing of chemotherapy initiation, suggesting that late administration of adjuvant chemotherapy may still be beneficial in appropriately selected patients.
本研究评估了可切除胰导管腺癌(PDAC)的辅助化疗时间与总生存期之间的关系。它还研究了近年来现代化疗方案的采用是否影响了这种关系,反映了不断发展的治疗实践。方法采用美国国家癌症数据库(NCDB)对可切除的原发性侵袭性PDAC病例进行鉴定。采用Kaplan Meier生存图和Cox比例风险模型可视化总生存期(OS)。分析协变量调整和倾向评分匹配的队列。采用Cox比例风险模型和logistic模型对匹配队列进行分析。结果31,949例患者纳入研究。26.4%的患者未接受化疗,66.4%的患者在12周内接受化疗,7.2%的患者在12周后接受化疗。mOS有显著改善。2015年至2019年期间,12周内接受化疗的患者的OS与12周内接受化疗的患者相比有显著差异。结论虽然可切除PDAC患者的辅助化疗与无辅助治疗相比可改善OS,但值得考虑的是,那些足够健康接受化疗的患者本身具有更好的预后。重要的是,无论化疗开始的时间如何,生存相关性仍然存在,这表明在适当选择的患者中,晚期辅助化疗可能仍然有益。
{"title":"The impact of the timing of adjuvant treatment initiation in patients with upfront resection of pancreatic cancer","authors":"Sydney McManus ,&nbsp;Aimée Galatas ,&nbsp;Sarah Hemelt ,&nbsp;Sanchit Sachdeva ,&nbsp;Kevin Sullivan ,&nbsp;Bolni Marius Nagalo ,&nbsp;Denise Danos ,&nbsp;Omeed Moaven","doi":"10.1016/j.suronc.2025.102329","DOIUrl":"10.1016/j.suronc.2025.102329","url":null,"abstract":"<div><h3>Introduction</h3><div>This study evaluates the association between timing of adjuvant chemotherapy and overall survival in resectable pancreatic ductal adenocarcinoma (PDAC). It also examines whether the adoption of modern chemotherapy regimens in recent years has influenced this relationship, reflecting evolving treatment practices.</div></div><div><h3>Methods</h3><div>Cases of resectable primary invasive PDAC were identified using the National Cancer Database (NCDB). Overall survival (OS) was visualized using Kaplan Meier survival plots and Cox proportional hazard models. Covariat adjustment and propensity score matched cohort were analyzed. The matched cohort was analyzed with Cox proportional hazard models and logistic models.</div></div><div><h3>Results</h3><div>31,949 patients were included in the study. 26.4 % received no chemotherapy, 66.4 % received chemotherapy within 12 weeks, and 7.2 % received chemotherapy after 12 weeks. There was significant improvement in mOS. Between 2015 and 2019, there was a significant difference in OS for patients receiving chemotherapy within 12 weeks, compared to &gt;12 weeks.</div></div><div><h3>Conclusion</h3><div>While adjuvant chemotherapy in patients with resectable PDAC is associated with improved OS compared to no adjuvant therapy, it is worth considering that those who are well enough to receive chemotherapy inherently have better prognoses. Importantly, the survival association persists regardless of the timing of chemotherapy initiation, suggesting that late administration of adjuvant chemotherapy may still be beneficial in appropriately selected patients.</div></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"64 ","pages":"Article 102329"},"PeriodicalIF":2.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145528651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cranial-to-caudal approach in laparoscopic surgery for left-sided colon cancer: Longer specimens and higher lymph node yield 左侧结肠癌腹腔镜手术颅尾入路:更长的标本和更高的淋巴结率。
IF 2.4 4区 医学 Q3 ONCOLOGY Pub Date : 2026-02-01 Epub Date: 2026-02-02 DOI: 10.1016/j.suronc.2026.102354
Beslen Goksoy , Cem B. Ofluoglu , Ibrahim F. Azamat , Gorkem Uzunyolcu , Serra Z. Akkoyunlu , Ilker Ozgur , Feza Ekiz

Background

Medial-to-lateral (ML) approach is the standard technique in laparoscopic surgery for left-sided colon cancer. However, it can be technically challenging; such as in patients with intra-abdominal adhesions or during splenic flexure mobilization. To overcome these difficulties, we adopted a cranial-to-caudal (CC) approach as an alternative technique. This study aimed to compare the CC and ML approaches in terms of short-term clinical and mid-term oncological outcomes.

Methods

Patients performed laparoscopic surgery for left-sided colon cancer between October 2018 and November 2022 were retrospectively analyzed. Patients were classified into two groups. The primary outcome was the length of the resected specimen. Secondary outcomes were pathological parameters, perioperative outcomes, recurrence-free survival (RFS) and overall survival (OS).

Results

Seventy-four patients were included (ML, n = 39; CC, n = 35). The CC group had longer specimen lengths compared with the ML group (32.9 ± 6.8 cm vs 28.9 ± 6.4 cm; p = 0.022), and longer proximal margin (11.8 ± 3.3 cm vs 9.9 ± 2.3 cm; p = 0.004). Lymph node yield was also higher in the CC group (26.4 ± 8.7 vs 22.3 ± 6.5; p = 0.033). On multivariable analysis, specimen length was independently associated with lymph node yield (β = 0.73; 95% CI, 0.47–1.20; p < 0.001). During a mean follow-up of 44 months, RFS (88.6% vs 89.7%; p = 0.84) and OS (88.6% vs 87.2%; p = 0.67) were similar between the groups.

Conclusions

In laparoscopic surgery for left-sided colon cancer, the CC approach yielded longer resected specimens and more lymph node counts compared with the ML approach, but did not improve oncologic outcomes.
背景:中外侧入路是左侧结肠癌腹腔镜手术的标准技术。然而,这在技术上可能具有挑战性;如腹腔粘连或脾屈曲活动时。为了克服这些困难,我们采用颅尾(CC)入路作为替代技术。本研究旨在比较CC和ML方法在短期临床和中期肿瘤预后方面的差异。方法:回顾性分析2018年10月至2022年11月行左侧结肠癌腹腔镜手术的患者。患者分为两组。主要结果是切除标本的长度。次要结局包括病理参数、围手术期结局、无复发生存期(RFS)和总生存期(OS)。结果:纳入74例患者(ML, n = 39; CC, n = 35)。与ML组相比,CC组的标本长度更长(32.9±6.8 cm比28.9±6.4 cm, p = 0.022),近端缘更长(11.8±3.3 cm比9.9±2.3 cm, p = 0.004)。CC组淋巴结率也较高(26.4±8.7 vs 22.3±6.5;p = 0.033)。在多变量分析中,标本长度与淋巴结产率独立相关(β = 0.73; 95% CI, 0.47-1.20; p)。结论:在腹腔镜下左侧结肠癌手术中,与ML入路相比,CC入路切除的标本更长,淋巴结计数更多,但并没有改善肿瘤预后。
{"title":"Cranial-to-caudal approach in laparoscopic surgery for left-sided colon cancer: Longer specimens and higher lymph node yield","authors":"Beslen Goksoy ,&nbsp;Cem B. Ofluoglu ,&nbsp;Ibrahim F. Azamat ,&nbsp;Gorkem Uzunyolcu ,&nbsp;Serra Z. Akkoyunlu ,&nbsp;Ilker Ozgur ,&nbsp;Feza Ekiz","doi":"10.1016/j.suronc.2026.102354","DOIUrl":"10.1016/j.suronc.2026.102354","url":null,"abstract":"<div><h3>Background</h3><div>Medial-to-lateral (ML) approach is the standard technique in laparoscopic surgery for left-sided colon cancer. However, it can be technically challenging; such as in patients with intra-abdominal adhesions or during splenic flexure mobilization. To overcome these difficulties, we adopted a cranial-to-caudal (CC) approach as an alternative technique. This study aimed to compare the CC and ML approaches in terms of short-term clinical and mid-term oncological outcomes.</div></div><div><h3>Methods</h3><div>Patients performed laparoscopic surgery for left-sided colon cancer between October 2018 and November 2022 were retrospectively analyzed. Patients were classified into two groups. The primary outcome was the length of the resected specimen. Secondary outcomes were pathological parameters, perioperative outcomes, recurrence-free survival (RFS) and overall survival (OS).</div></div><div><h3>Results</h3><div>Seventy-four patients were included (ML, n = 39; CC, n = 35). The CC group had longer specimen lengths compared with the ML group (32.9 ± 6.8 cm vs 28.9 ± 6.4 cm; p = 0.022), and longer proximal margin (11.8 ± 3.3 cm vs 9.9 ± 2.3 cm; p = 0.004). Lymph node yield was also higher in the CC group (26.4 ± 8.7 vs 22.3 ± 6.5; p = 0.033). On multivariable analysis, specimen length was independently associated with lymph node yield (β = 0.73; 95% CI, 0.47–1.20; p &lt; 0.001). During a mean follow-up of 44 months, RFS (88.6% vs 89.7%; p = 0.84) and OS (88.6% vs 87.2%; p = 0.67) were similar between the groups.</div></div><div><h3>Conclusions</h3><div>In laparoscopic surgery for left-sided colon cancer, the CC approach yielded longer resected specimens and more lymph node counts compared with the ML approach, but did not improve oncologic outcomes.</div></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"64 ","pages":"Article 102354"},"PeriodicalIF":2.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146127192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk reduction bilateral salpingo-oophorectomy with vNOTES: A new era in cancer prevention strategies 风险降低双侧输卵管卵巢切除术与vNOTES:癌症预防策略的新时代。
IF 2.4 4区 医学 Q3 ONCOLOGY Pub Date : 2026-02-01 Epub Date: 2026-01-02 DOI: 10.1016/j.suronc.2025.102349
Maria Pellisé-Tintoré , Thomas Gaillard , Enora Laas , Virginie Fourchotte , Hélène Didelot , Lea Pauly , Jean Guillaume Feron , Fabien Reyal , Fabrice Lecuru

Introduction

Women with BRCA1 and BRCA2 mutations face a significantly increased lifetime risk of developing ovarian and fallopian tube cancer. Minimally invasive techniques are the gold standard access to perform risk-reduction operations. This study aims to evaluate the feasibility and safety of prophylactic bilateral salpingo-oophorectomy using the vaginal natural orifice transluminal endoscopic surgery (vNOTES) technique as a risk-reduction strategy.

Material and methods

A prospective study was conducted between October 2023 and December 2024, involving 25 high-risk women at an international, university-affiliated cancer center. All patients underwent prophylactic bilateral salpingo-oophorectomy via transvaginal access using vNOTES. Key data collected included age, BMI, operative time, and blood loss, with primary outcomes focusing on feasibility, complications, and recovery.

Results

Twenty-five BRCA-mutated patients underwent prophylactic bilateral adnexectomy via vNOTES. Median age was 48 years (range 41–59) and median BMI 24.1 kg/m2 (range 19.1–30.4). All procedures were completed without conversion to laparoscopy or laparotomy, and vNOTES enabled full abdominal exploration. Median operative time was 40 min (IQR 32–44), with minimal blood loss (<100 mL in 96 %) and no intraoperative complications. Postoperative recovery was uneventful, with no pain reported and 96 % of patients discharged the same day. No late complications related to the surgical technique were observed.

Conclusion

Prophylactic bilateral salpingo-oophorectomy using the vNOTES technique appears to be a feasible and safe option for reducing the risk of ovarian and fallopian tube cancers in high-risk women. Further studies with larger cohorts are needed to validate these findings.
简介:携带BRCA1和BRCA2突变的女性患卵巢癌和输卵管癌的风险显著增加。微创技术是进行降低风险手术的黄金标准。本研究旨在评估使用阴道自然口腔内内镜手术(vNOTES)技术作为降低风险策略的预防性双侧输卵管卵巢切除术的可行性和安全性。材料和方法:一项前瞻性研究于2023年10月至2024年12月进行,涉及一家国际大学附属癌症中心的25名高风险女性。所有患者均采用vNOTES经阴道预防性双侧输卵管卵巢切除术。收集的关键数据包括年龄、BMI、手术时间和出血量,主要结局关注可行性、并发症和恢复情况。结果:25例brca突变患者通过vNOTES行预防性双侧附件切除术。中位年龄为48岁(范围41-59),中位BMI为24.1 kg/m2(范围19.1-30.4)。所有手术均在未转为腹腔镜或开腹手术的情况下完成,vNOTES实现了全腹探查。中位手术时间为40分钟(IQR 32-44),出血量最小(结论:使用vNOTES技术预防性双侧输卵管-卵巢切除术似乎是降低高危妇女卵巢癌和输卵管癌风险的可行和安全的选择。需要更大规模的进一步研究来验证这些发现。
{"title":"Risk reduction bilateral salpingo-oophorectomy with vNOTES: A new era in cancer prevention strategies","authors":"Maria Pellisé-Tintoré ,&nbsp;Thomas Gaillard ,&nbsp;Enora Laas ,&nbsp;Virginie Fourchotte ,&nbsp;Hélène Didelot ,&nbsp;Lea Pauly ,&nbsp;Jean Guillaume Feron ,&nbsp;Fabien Reyal ,&nbsp;Fabrice Lecuru","doi":"10.1016/j.suronc.2025.102349","DOIUrl":"10.1016/j.suronc.2025.102349","url":null,"abstract":"<div><h3>Introduction</h3><div>Women with BRCA1 and BRCA2 mutations face a significantly increased lifetime risk of developing ovarian and fallopian tube cancer. Minimally invasive techniques are the gold standard access to perform risk-reduction operations. This study aims to evaluate the feasibility and safety of prophylactic bilateral salpingo-oophorectomy using the vaginal natural orifice transluminal endoscopic surgery (vNOTES) technique as a risk-reduction strategy.</div></div><div><h3>Material and methods</h3><div>A prospective study was conducted between October 2023 and December 2024, involving 25 high-risk women at an international, university-affiliated cancer center. All patients underwent prophylactic bilateral salpingo-oophorectomy via transvaginal access using vNOTES. Key data collected included age, BMI, operative time, and blood loss, with primary outcomes focusing on feasibility, complications, and recovery.</div></div><div><h3>Results</h3><div>Twenty-five BRCA-mutated patients underwent prophylactic bilateral adnexectomy via vNOTES. Median age was 48 years (range 41–59) and median BMI 24.1 kg/m<sup>2</sup> (range 19.1–30.4). All procedures were completed without conversion to laparoscopy or laparotomy, and vNOTES enabled full abdominal exploration. Median operative time was 40 min (IQR 32–44), with minimal blood loss (&lt;100 mL in 96 %) and no intraoperative complications. Postoperative recovery was uneventful, with no pain reported and 96 % of patients discharged the same day. No late complications related to the surgical technique were observed.</div></div><div><h3>Conclusion</h3><div>Prophylactic bilateral salpingo-oophorectomy using the vNOTES technique appears to be a feasible and safe option for reducing the risk of ovarian and fallopian tube cancers in high-risk women. Further studies with larger cohorts are needed to validate these findings.</div></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"64 ","pages":"Article 102349"},"PeriodicalIF":2.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145936141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Surgical Oncology-Oxford
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1